Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Eligible patients will receive either AP or matching placebo in a double blind, randomized
design and following a 2:1 ratio. All medication will be given in addition to standard care
for sepsis patients. Patients will be followed for 28 days after the start of study
medication administration. A blinded safety review of the study results will take place after
the inclusion of 12 patients in the study.